IS7671A - Ónæmisvaka samsetningar - Google Patents

Ónæmisvaka samsetningar

Info

Publication number
IS7671A
IS7671A IS7671A IS7671A IS7671A IS 7671 A IS7671 A IS 7671A IS 7671 A IS7671 A IS 7671A IS 7671 A IS7671 A IS 7671A IS 7671 A IS7671 A IS 7671A
Authority
IS
Iceland
Prior art keywords
carbohydrate
parenteral
antigen
sublimation
administration
Prior art date
Application number
IS7671A
Other languages
English (en)
Inventor
Vande Velde Vincent
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of IS7671A publication Critical patent/IS7671A/is

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IS7671A 2002-08-13 2005-01-27 Ónæmisvaka samsetningar IS7671A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0218821.7A GB0218821D0 (en) 2002-08-13 2002-08-13 Novel compositions
PCT/EP2003/009010 WO2004016241A1 (en) 2002-08-13 2003-08-12 Antigenic compositions

Publications (1)

Publication Number Publication Date
IS7671A true IS7671A (is) 2005-01-27

Family

ID=9942239

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7671A IS7671A (is) 2002-08-13 2005-01-27 Ónæmisvaka samsetningar

Country Status (19)

Country Link
US (1) US20060051372A1 (is)
EP (1) EP1528914B1 (is)
JP (1) JP2006500358A (is)
KR (1) KR20050056965A (is)
CN (1) CN1674867A (is)
AT (1) ATE409459T1 (is)
AU (1) AU2003255440A1 (is)
BR (1) BR0313337A (is)
CA (1) CA2494002A1 (is)
DE (1) DE60323842D1 (is)
GB (1) GB0218821D0 (is)
IL (1) IL166526A0 (is)
IS (1) IS7671A (is)
MX (1) MXPA05001728A (is)
NO (1) NO20050543L (is)
PL (1) PL375590A1 (is)
RU (1) RU2005102589A (is)
WO (1) WO2004016241A1 (is)
ZA (1) ZA200500833B (is)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050002958A1 (en) * 1999-06-29 2005-01-06 Smithkline Beecham Biologicals Sa Vaccines
EP2272502A1 (en) * 2003-12-19 2011-01-12 Alk-Abelló A/S Cryogranules of a liquid composition of an allergen product
US20080145383A1 (en) * 2004-03-12 2008-06-19 Intercell Ag Method for Solubilizing Peptide Mixtures
US20080226729A1 (en) * 2006-09-08 2008-09-18 Becton, Dickinson And Company Stable powder formulations of alum-adsorbed vaccines
JP2008096503A (ja) * 2006-10-06 2008-04-24 Toshiba Corp 粉末状感光性組成物の製造方法、感光性組成物およびこの感光性組成物から形成された光記録媒体
EP2148697B1 (en) * 2007-05-24 2012-10-03 GlaxoSmithKline Biologicals S.A. Lyophilised cpg containing wt-1 composition
EP2200642B1 (en) * 2007-10-19 2012-04-18 Novartis AG Meningococcal vaccine formulations
US20160317646A1 (en) * 2013-12-19 2016-11-03 Crucell Holland B.V. Formulations for virosomes
WO2016138362A1 (en) * 2015-02-26 2016-09-01 The Board Of Trustees Of The University Of Arkansas Treatment vaccine for prostate cancer
KR20190057345A (ko) * 2016-09-21 2019-05-28 아말 테라퓨틱스 에스에이 암 치료를 위한, 세포 투과 펩타이드, 멀티 에피토프 및 tlr 펩타이드 작용제를 포함하는 융합체
BR112021000529A2 (pt) * 2018-07-19 2021-04-06 Glaxosmithkline Biologicals S.A. Processos para preparar polissacarídeos secos
CN117100707A (zh) * 2023-10-19 2023-11-24 江苏瑞科生物技术股份有限公司 一种针对hpv免疫原性蛋白的冻干保护剂及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3186908A (en) * 1962-08-16 1965-06-01 Parke Davis & Co Calcium lactobionate stabilization of labile antigenic virus vaccine materials
DE3585835D1 (de) * 1984-12-07 1992-05-14 Faruk Hadziselimovic Praeparat zur intramuskulaeren injektion von medikamenten, vitaminen oder impfstoffen.
US4895716A (en) * 1987-06-09 1990-01-23 Biogen, Inc. Stabilized formulations of gamma interferons
FR2733151B1 (fr) * 1995-04-20 1997-05-23 Seppic Sa Composition therapeutique comprenant un antigene ou un generateur in vivo d'un compose comprenant une sequence d'acides amines
NZ505324A (en) * 1997-12-22 2002-11-26 Human Genome Sciences Inc Liquid and lyophilised KGF-2 polypeptide formulations used to accelerate soft tissue growth or regeneration

Also Published As

Publication number Publication date
MXPA05001728A (es) 2005-05-27
PL375590A1 (en) 2005-11-28
CN1674867A (zh) 2005-09-28
KR20050056965A (ko) 2005-06-16
BR0313337A (pt) 2005-06-14
EP1528914A1 (en) 2005-05-11
NO20050543L (no) 2005-03-11
AU2003255440A1 (en) 2004-03-03
JP2006500358A (ja) 2006-01-05
CA2494002A1 (en) 2004-02-26
WO2004016241A1 (en) 2004-02-26
GB0218821D0 (en) 2002-09-18
ZA200500833B (en) 2006-08-30
ATE409459T1 (de) 2008-10-15
IL166526A0 (en) 2006-01-15
DE60323842D1 (de) 2008-11-13
EP1528914B1 (en) 2008-10-01
RU2005102589A (ru) 2005-10-10
US20060051372A1 (en) 2006-03-09

Similar Documents

Publication Publication Date Title
IS7671A (is) Ónæmisvaka samsetningar
DK2709657T3 (en) Thermostable vaccine compositions and methods for their preparation
Tonnis et al. Improved storage stability and immunogenicity of hepatitis B vaccine after spray-freeze drying in presence of sugars
DE60121136D1 (de) Proteasom-influenzavirus-impfstoffzusammensetzung
EP0919243A1 (en) Vaccine containing B subunits of heat-labile enterotoxin (LTB) of Escherichia coli as an adjuvant
US20090208523A1 (en) Adjuvant for vaccines
MXPA03001392A (es) Vacuna de dosis solida oral.
WO2010146598A2 (en) Stable, dried rotavirus vaccine, compositions and process for preparation thereof
Gerdts et al. Carrier molecules for use in veterinary vaccines
KR20050084575A (ko) 백신의 개선 또는 백신에 관한 개선
JP2011514337A5 (is)
TW200738257A (en) Vaccine
AU2016210743A1 (en) Inactivated dengue virus vaccine
Isibasi et al. Active protection of mice against Salmonella typhi by immunization with strain-specific porins
Böhles et al. Vaccines against human diarrheal pathogens: current status and perspectives
RU2014151424A (ru) Термостабильные составы вакцины
KR20180043352A (ko) 다가 vlp 접합체
KR20180041237A (ko) Vlp 안정화된 백신 조성물
WO2018231706A1 (en) Methods and compositions for substance use disorder vaccine formulations and uses thereof
KR101867428B1 (ko) 경구 백신 투여용의 개선된 항원보강제 시스템
Tafuku et al. Japanese encephalitis virus structural and nonstructural proteins expressed in Escherichia coli induce protective immunity in mice
ATE416788T1 (de) Verwendung von pflanzen-öl-körper in impfstoffverabreichungsysteme
JP2015091795A (ja) 鼻粘膜ワクチン組成物
Yang et al. Construction and immune effect evaluation of the S protein heptad repeat-based nanoparticle vaccine against porcine epidemic diarrhea virus
CN101296705A (zh) 固体疫苗制剂